HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.

Abstract
Rhabdomyolysis is a clinical syndrome in which skeletal muscle damage and necrosis leads to the release of intracellular muscle contents, which can ultimately lead to electrolyte disturbances, renal failure and even death. Chemotherapy is an extremely rare cause of rhabdomyolysis. Herein, we describe a fatal case of rhabdomyolysis in a patient with metastatic sarcoma after receiving the chemotherapeutic agent Ecteinascidin-743 (ET-743, trabectedin) as palliative chemotherapy treatment.
AuthorsAmy Skorupa, Matthew Beldner, Andrew Kraft, Alberto J Montero
JournalCancer biology & therapy (Cancer Biol Ther) Vol. 6 Issue 7 Pg. 1015-7 (Jul 2007) ISSN: 1538-4047 [Print] United States
PMID17611408 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Dioxoles
  • Tetrahydroisoquinolines
  • Trabectedin
Topics
  • Antineoplastic Agents, Alkylating (adverse effects)
  • Dioxoles (adverse effects)
  • Fatal Outcome
  • Humans
  • Male
  • Middle Aged
  • Rhabdomyolysis (chemically induced)
  • Sarcoma (drug therapy)
  • Tetrahydroisoquinolines (adverse effects)
  • Trabectedin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: